NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis $49.64 -0.37 (-0.74%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Q32 Bio Stock (NASDAQ:QTTB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Q32 Bio alerts:Sign Up Key Stats Today's Range$48.00▼$50.2250-Day Range$34.43▼$50.0152-Week Range$8.24▼$53.79Volume91,215 shsAverage Volume66,384 shsMarket Capitalization$592.80 millionP/E RatioN/ADividend YieldN/APrice Target$68.80Consensus RatingBuy Company OverviewQ32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Read More… Don’t Buy Another Stock Until Reading This… (Ad)Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my upcoming FREE intro to investing online event, my team will be revealing the strategies I've developed over the past 37 years on Wall Street…Click here to claim your seat at my Intro to Investing class now! Q32 Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks38th Percentile Overall ScoreQTTB MarketRank™: Q32 Bio scored higher than 38% of companies evaluated by MarketBeat, and ranked 778th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingQ32 Bio has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageQ32 Bio has only been the subject of 1 research reports in the past 90 days.Read more about Q32 Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($11.76) to ($4.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Q32 Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.08% of the float of Q32 Bio has been sold short.Short Interest Ratio / Days to CoverQ32 Bio has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Q32 Bio has recently increased by 27.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.08% of the float of Q32 Bio has been sold short.Short Interest Ratio / Days to CoverQ32 Bio has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Q32 Bio has recently increased by 27.24%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.68 News SentimentQ32 Bio has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Q32 Bio this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have not sold or bought any company stock.Percentage Held by Insiders16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address QTTB Stock News HeadlinesOppenheimer Maintains Bullish Stance on Q32 Bio with Robust Clinical OutlookOctober 16 at 5:02 PM | finance.yahoo.comQ32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024October 14, 2024 | prnewswire.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.October 18, 2024 | Weiss Ratings (Ad)Q32 Bio (NASDAQ:QTTB) Shares Up 4.8% - Time to Buy?October 10, 2024 | americanbankingnews.comQ32 BIO INC. O.N. (DB0.BE)September 20, 2024 | nz.finance.yahoo.comQ32 Bio Inc. (DB0.F)September 13, 2024 | uk.finance.yahoo.comWells Fargo Initiates Coverage of Q32 Bio (QTTB) with Overweight RecommendationSeptember 11, 2024 | msn.comQ32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097August 29, 2024 | seekingalpha.comSee More Headlines QTTB Stock Analysis - Frequently Asked Questions How have QTTB shares performed this year? Q32 Bio's stock was trading at $17.04 on January 1st, 2024. Since then, QTTB stock has increased by 191.3% and is now trading at $49.64. View the best growth stocks for 2024 here. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by $0.42. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Q32 Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Stock Price Target$68.80 High Stock Price Target$100.00 Low Stock Price Target$45.00 Potential Upside/Downside+38.6%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($32.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net MarginsN/A Pretax Margin-22,326.84% Return on Equity-129.44% Return on Assets-62.88% Debt Debt-to-Equity Ratio0.37 Current Ratio6.49 Quick Ratio6.49 Sales & Book Value Annual Sales$-6,651,000.00 Price / Sales-89.13 Cash FlowN/A Price / Cash FlowN/A Book Value$22.47 per share Price / Book2.21Miscellaneous Outstanding Shares11,942,000Free Float10,118,000Market Cap$592.80 million OptionableN/A Beta-0.32 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:QTTB) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.